MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-026-08029-4

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2026

Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.

Frega Juliette, Somme Laura, Martin Tristan, Petit Thierry, Salvadori Julien, Bund Caroline, Somme François

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Trastuzumab deruxtecan (T-DXd) has recently reshaped the management of HER2-low metastatic breast cancer. While pivotal trials relied on CT-based RECIST 1.1, [18F]FDG PET/CT provides high diagnostic sensitivity and valuable semi-quantitative metrics, though its role in monitoring antibody-drug conjugates remains insufficiently defined. This study assessed the prognostic value of PET-derived parameters and PERCIST criteria in patients treated with T-DXd.

METHODS

This retrospective study included all HER2-low metastatic breast cancer patients treated with T-DXd between 2022 and 2025 at the Strasbourg Europe Cancer Institute (ICANS) who underwent [18F]FDG PET/CT. Semi-quantitative parameters (SUVmax, SULpeak) and metabolic response according to PERCIST 1.0 were collected. Their association with overall survival (OS), metabolic progression-free survival (mPFS) and time-to-treatment change (TTT) was analyzed using Cox models and Kaplan-Meier curves.

RESULTS

Forty-three patients were included. Baseline SULpeak of the most hypermetabolic lesion was an independent prognostic factor for OS, mPFS and TTT (p < 0.05). A ROC-derived cutoff of 6 identified two prognostic groups, with SULpeak < 6 associated with significantly improved outcomes. Early metabolic response was also linked to longer OS and PFS (p< 0.05), with median PFS of 9.2 vs. 4.2 months (HR 2.67; 95% CI 1.30-5.47). Combining baseline SULpeak and metabolic response (complete or partial metabolic response) defined three risk groups with significantly different OS and PFS.

CONCLUSION

[18F]FDG PET/CT provides significant prognostic information in HER2-low metastatic breast cancer treated with T-DXd. Baseline SULpeak and early PERCIST response enable meaningful risk stratification. The proposed prognostic model requires prospective validation before clinical implementation.

Для цитирования: Frega Juliette, Somme Laura, Martin Tristan, Petit Thierry, Salvadori Julien, Bund Caroline, Somme François. Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.. European journal of nuclear medicine and molecular imaging. 2026. DOI: 10.1007/s00259-026-08029-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.